Forty years of chemistry that customers cannot easily source elsewhere, earning 6.9% on capital. Aarti Industries makes benzene- and toluene-based intermediates and sulphuric acid derivatives — over 100 products from 16 plants in western India, sold to more than 1,100 customers in 60 countries and ending up in agrochemicals, dyes and inks, fuel additives, pharmaceuticals and polymers. It is fully backward integrated on benzene, and India Ratings ranks it among the top three globally in the chlorination, nitration, ammonolysis and hydrogenation chemistry of that value chain. Over 85% of FY26 revenue came from customers of more than ten years. That 6.9% is below every one of the seven specialty chemicals companies covered here — Gujarat Fluorochemicals at 9.7% is the nearest, and Navin Fluorine earns 21.2%. Revenue grew 14% in FY26 to ₹8,286 crore (consolidated), so the growth is real enough. The return on it is not.
Strong on the measures that take decades to build, weak on the ones that move each quarter. Integration and stickiness are where it scores. It is fully backward integrated on benzene with domestic supply, so its main raw material is not an import; over 85% of FY26 revenue came from relationships older than ten years; exports were 57% of revenue, across 60 countries. Concentration is where it does not. Fuel additives grew to 43% of FY26 revenue from 36% the year before, and the West Asia conflict cut that region from roughly 15% of revenue to 2% inside a single quarter. Utilisation is disclosed as bands rather than numbers. In Q1 FY27 the PDA chain ran below 65% on weak US demand and Chinese competition, while other chains ran above 85%.
Carrying real debt, and the plan to bring it down has already slipped. Borrowings were ₹4,966 crore at FY26 against ₹609 crore of cash — ₹4,357 crore of net debt on ₹5,955 crore of shareholders' funds, debt to equity 0.83, net leverage near 3.7 times. India Ratings affirmed IND AA in February 2026 but cut the outlook to Negative, citing a delay in deleveraging. Its own series runs 2.5 times in FY23, 3.5 in FY24, 3.6 in FY25 and 3.8 at the FY26 half-year. ₹2,030 crore of the balance sheet is capital work in progress — plants carrying the debt without yet earning against it. Management targets leverage below 2.5 times by FY28 on EBITDA of ₹1,800–2,200 crore. That gap is the case and the risk in one number.
Record sales, and a third of the profit the company made on less of them four years ago. FY26 revenue was ₹8,286 crore, up 14%, with profit of ₹419 crore, up 27%. In FY22 it earned ₹1,186 crore on ₹6,086 crore of sales — less revenue, nearly three times the profit. The EBITDA margin tells the story more plainly than the growth rate: 28.3% in FY22, then 16.5%, 15.4%, 13.8%, and 14.1% in FY26. The first uptick in four years is real, and it is one third of a point. Note that FY26 profit before tax was ₹365 crore. It became ₹419 crore after a net tax credit of ₹54 crore.
Profit is growing faster than sales, and is still a third of what it was four years ago. Revenue reached ₹8,286 crore in FY26 from ₹7,271 crore, compounding 13% over five years. Profit was ₹419 crore against ₹331 crore — but compounded at minus 4.4% over the same five years, because FY22's ₹1,186 crore is the peak everything since is measured from. Most of the FY26 revenue increase came from fuel additives, where capacity went from 200 to 290 KTPA and the segment grew to 43% of revenue. Volume, in other words, not price.
Built, not bought — and increasingly built with partners rather than alone. There have been no acquisitions. Growth has come from plants: fuel additives capacity from 200 to 290 KTPA in FY26 and to 360 KTPA in July 2026, DCB debottlenecking towards 140 KTPA, and the Zone IV complex of five chemistry blocks. FY27 capex is guided at ₹700–800 crore. The newer pattern is joint ventures. Augene Chemical, 50:50 with Superform, commissions in Q2 FY27 with steady-state revenue projected at ₹300–400 crore; Re-Aarti, for chemical recycling of plastics, follows in the second half. Zone IV has slipped three to six months on labour shortages, with 97% of equipment erected and 85% of piping done. Management calls it "a pure product execution challenge", not a demand one.
Halved since FY22, and the recovery so far is a rounding error. The EBITDA margin was 28.3% in FY22. It has been 16.5%, 15.4%, 13.8% and now 14.1% — an improvement of a third of a point on FY25, on revenue 14% higher. That 14.1% is the second thinnest of the eight specialty chemicals companies covered here, above Deepak Nitrite at 12.5% and against 32.6% at Navin Fluorine and 35.9% at Acutaas. Q1 FY27 looked far better — EBITDA of ₹385 crore, up 79% — but management attributed ₹50–60 crore of it to inventory and currency gains, on a rupee that moved between ₹92 and ₹97 inside the quarter.
No. 6.92%, and that is the improvement. Return on capital employed was 6.92% in FY26 against 6.35% in FY25. The path there: 21.9% in FY22, then 10.4%, 7.3% and 6.4%. It is the lowest of the seven specialty chemicals companies covered alongside it — Gujarat Fluorochemicals earns 9.7%, SRF 14.1%, Navin Fluorine 21.2%, Acutaas 32.3%. Part of the explanation is sitting in the denominator doing nothing: ₹2,030 crore of capital work in progress inside ₹10,921 crore of capital employed. Roughly a fifth of the capital is in plants that have not started.
Cash has been the reliable part, and last year it fell by nearly two fifths. Operating cash flow was ₹775 crore in FY26 against ₹1,242 crore in FY25. Over three years cash from operations has been 2.8 times reported profit, against depreciation of ₹474 crore in FY26 alone. Collections are not the problem: debtors run 61.8 days and inventory 76.3 days. The pressure came in the June quarter, when working capital expanded on higher feedstock prices and longer export voyages to the United States, and management said debt and finance costs rose to fund it. Finance costs were already ₹340 crore in FY26 against ₹275 crore.
A family business that has given away the chief executive's job and half the boardroom. The board is fourteen strong, of whom seven are independent — exactly half. Six are executives, and three of those are Gogris: Rajendra V. Gogri as Chairman and Managing Director, Rashesh C. Gogri as Vice Chairman and Managing Director, Renil R. Gogri as Vice Chairman. Chandrakant V. Gogri, who founded the company in 1984 and stepped down as chairman in 2012, is Chairman Emeritus. The other three executive seats are held by professionals. Suyog K. Kotecha became Chief Executive in June 2024, runs the earnings calls, and answers on them plainly enough to call the PDA chain one where "we structurally remain weak because of our technological disadvantage". The chairman is also a managing director, so those roles are not separated, and four non-executive directors joined only in 2024. Half-independent with an outside chief executive is a stronger structure than most family-controlled chemical companies carry.
A clean opinion on both sets of accounts, and a provision that is still an estimate. Gokhale & Sathe signed the standalone and consolidated FY26 accounts with unmodified opinions and no emphasis of matter. Eight subsidiaries — five Indian, three overseas, carrying ₹1,716 crore of revenue — were audited by other firms and disclosed as an Other Matter, which is routine. Claims not acknowledged as debts were ₹109.83 crore at March 2026, up from ₹85.61 crore, against ₹5,955 crore of net worth. Letters of credit, bank guarantees and bills discounted more than doubled to ₹493.20 crore. Exceptional items netted to ₹6 crore from three entries pulling against each other: ₹28.50 crore of interest income on tax appeals won for years back to 2010-11, ₹6.67 crore provided against a land advance to an infrastructure lender in financial distress, and ₹15.37 crore set aside for the four new labour codes — a figure the company says it will revise as the rules are finalised.
A real edge in some chains, and a stated disadvantage in one. Aarti competes with global benzene-chain producers and, increasingly, with Chinese capacity. Its edge is integration and scale in a narrow chemistry: top three globally in the chlorination, nitration, ammonolysis and hydrogenation of the benzene chain, and top four in 75% of its portfolio with 25–40% share, on management's numbers as reported by India Ratings. The edge is not uniform. Management calls the PDA chain one where "we structurally remain weak because of our technological disadvantage", and says fuel additives — the fastest-growing part — already has two or three Indian entrants and as many Chinese ones. What a rival cannot copy quickly is the qualification: over 85% of revenue comes from customers of more than a decade, and Zone IV's own new molecules still need commercial-batch approval before they sell.
Second largest of the eight covered here, and last on almost everything else. By revenue Aarti's ₹8,286 crore sits behind SRF's ₹15,787 crore and ahead of Deepak Nitrite's ₹7,887 crore and PI Industries' ₹6,714 crore. On returns it is last: 6.92% against Deepak Nitrite 11.4%, Aether 11.6%, SRF 14.1%, PI 15.9%, Navin Fluorine 21.2%, Acutaas 32.3%. Margins rank seventh of eight at 14.1%, ahead only of Deepak Nitrite. On leverage it is the most indebted of the eight: debt to equity 0.83, where the next highest is SRF at 0.36 and PI carries 0.03. It grew faster in FY26 than PI Industries, Deepak Nitrite, Gujarat Fluorochemicals and SRF, and slower than Acutaas, Aether and Navin Fluorine. Size has not bought it the economics that the smaller, more specialised companies have.
Two policy tailwinds, one war, and a project that keeps slipping. Helping: China removed the export VAT rebate on major NCB-chain products from April 2026, which management says changed the pricing regime across the chain and lifted margins. India Ratings also points to the US–India trade deal and an India–EU free trade agreement as supports. Gasoline–naphtha cracks at $15–20 a barrel keep fuel additive demand strong. Hurting: the West Asia conflict took that region from roughly 15% of revenue to 2% in a quarter, and overall volumes fell 12% quarter-on-quarter in Q1 FY27 — energy down 17%, non-energy down 7%. Elevated benzene, sulphur, methanol and aniline prices pushed customers in dyes, some agrochemicals and polymers to delay buying. The structural risk is closer to home. Zone IV has slipped three to six months, FY28 guidance assumes it ramps, and Aarti is carrying ₹4,357 crore of net debt while it waits. Raw materials are crude-linked, and management is candid that a sharp fall in prices turns this year's inventory gains into next year's inventory losses.
The cycle that matters here is not India's, it is the world's spare capacity. Aarti sells intermediates into a market where price is set by the marginal producer worldwide, so its fortunes track global spare capacity rather than Indian demand. That is why its margin halved after the COVID years without a single plant closing. The turn, if it comes, shows up in the same place: crackers idled or shut in Europe, Japan and South Korea, and Chinese expansion slowing. Aarti's chief executive gave the honest version in July 2026 — demand could meet capacity around 2028–29 and restructure industry margins, but "that is a personal hypothesis, and I guess we have to wait at least 2 or 3 more years to see if it pans out." Nearer term it is Chinese policy, not Indian demand, doing the work: withdrawing the export VAT rebate repriced a whole value chain in a quarter.
You are paying nearly 47 times earnings for a business earning 6.9% on its capital. At ₹538.90 on 27 August 2026 the shares traded at 46.6 times earnings, 3.3 times book and 2.4 times sales, capitalising the company at ₹19,540 crore. The earnings yield is 2.1%. Those earnings are ₹419 crore, a third below FY22's ₹1,186 crore, and ₹54 crore of the FY26 figure came from a net tax credit rather than trading. The case rests entirely on the FY28 target — EBITDA of ₹1,800–2,200 crore against ₹1,168 crore now. On that, the multiple is reasonable. On what the company earns today, it is not.
Dearer than its earnings deserve, and mid-table against its peers. The shares were at 46.6 times earnings on 27 August 2026. Among the eight specialty chemicals companies covered here that is dearer than PI Industries at 28.3, SRF at 41.7 and Deepak Nitrite at 44.0, and cheaper than Navin Fluorine at 66.1, Acutaas at 74.9, Gujarat Fluorochemicals at 92.6 and Aether at 100.1. The multiple looks moderate in that company, but the earnings underneath it do not. Every company priced above Aarti earns at least 9.7% on capital; Aarti earns 6.92%. On sales it is the cheapest of the eight at 2.4 times, against Acutaas at 19.9 and Navin at 13.2 — which is the same fact seen from the other end. Thin margins buy you a low multiple of revenue.
One in eight small shareholders left the register over the year, and institutions took the stock. Institutional holding rose to 28.10% at June 2026, up 1.28 points over four quarters — domestic from 20.38% to 21.11%, foreign from 6.44% to 6.99%. Mutual funds hold 12.12%. On the other side, the shareholder count fell from 425,399 to 370,868 across the same four quarters, down 12.8%, and public holding slipped from 30.93% to 30.06%. Retail sold into a 43% rise. Institutions bought it.
Life Insurance Corporation has held exactly 6.8% for six straight quarters. At June 2026 the holders above 1% were LIC at 6.8%, ICICI Prudential at 4.46%, HDFC Mutual Fund at 2.5%, Nippon Life India Trustee at 1.66% and Mahindra Manulife Multi Cap Fund at 1.19%. ICICI Prudential is the one that has moved: 3.37% in March 2025, then 2.96%, 3.11%, 3.29%, 3.53% and 4.46% — almost a point added in the June quarter alone. Mahindra Manulife is new above 1%. LIC's 6.8% has not changed by a single reported basis point across all six filings held, which is its own kind of statement.
A token dividend, no buyback, and no new shares since 2022. The board recommended ₹1 a share for FY26, costing ₹36.26 crore — 8.6% of profit. It was ₹1 the year before too. Share count has been effectively unchanged since the qualified institutions placement of 1,40,35,087 shares in FY22, which accounts for almost all of the 4.1% dilution over five years. There has been no buyback. Where the money has actually come from is lenders. Financing activities brought in ₹745 crore during FY26 against no meaningful change in the share count, which is borrowing, not equity — and it went into the ₹2,030 crore of construction sitting on the balance sheet.
Loading…